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1. Introduction 
For close to a century, researchers have known that Papillomavirus infections in humans 
cause a variety of benign proliferations including warts, epithelial cysts, intraepithelial 
neoplasias, oral laryngeal, pharyngeal papillomas and other types of hyperkeratosis. 
However the molecular mechanisms involved are far from understood. HPV has been 
detected in more than 90% of cervical cancers and therefore implicated as the main 
etiological agents in cervical cancer. The pathogenesis of cervical cancer is well-known to 
involve a multi-step process that includes the transformation of normal cervical epithelium 
to pre-neoplastic cervical intraepithelial neoplasia that is subsequently transformed to 
invasive cervical cancer. Although the causal relationship between high-risk human 
papillomavirus (HPV) infection and cervical cancer has been well-documented in 
epidemiologic and functional studies, HPV infection alone is not sufficient to induce the 
malignant transformation of HPV-infected cells. Hence, other unidentified genetic 
alterations, such as microRNAs the master switches, are required. A class of molecules 
discovered quite recently, microRNAs (miRNAs), appear to play a significant role in cell 
proliferation and differentiation, and aberrant miRNAs are associated with several cancers. 
An new era focusing on micro RNAs, and the studies on HPV and host miRNA interactions 
will continue shedding more light on understanding of the HPV life cycle and the 
mechanistic underpinnings of HPV-induced oncogenesis. 
These small non-coding RNAs can contribute to the repertoire of host pathogen interactions 
during viral infection. This interplay has important consequences, both for the virus and the 
host. There has been reported evidence of host-cellular miRNAs modulating expression of 
various viral genes, thereby playing a pivotal role in the host–pathogen interaction network. 
In the hide-and-seek game between the pathogens and the infected host, viruses have 
evolved highly sophisticated gene-silencing mechanisms to evade host-immune response. 
Recent reports indicate that virus also encode miRNAs that protect them against cellular 
antiviral response. Furthermore, they may exploit the cellular miRNA pathway to their own 
advantage. This chapter aims to summarize our current knowledge about miRNA profiles in 
cervical cancer cell lines and tissues as well as recapitulate recent updates on miRNA-
induced gene-silencing mechanism; modulating host–virus interactions of HPV integrated 
Cervical Carcinomas. 
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2. Human papillomaviruses and cervical cancer 
Cervical cancer is the second most common life-threatening cancer among women 
worldwide, with 493,243 new cases and nearly 273,505 deaths per year (Parkin et al., 2005, 
2006). In 2010, there were an estimated 12,200 new cases and an associated 4,210 deaths, 
accounting for approximately 1% of cancer deaths in women (Jemal et al., 2010). In 1995 the 
World Health Organization (WHO) declared HPV as a known carcinogen for causing factor 
for cervical cancer, because DNA of mucosal high-risk HPV types could be detected in 
almost all cervical cancers (Walboomers et al., 1999). Persistent infection with oncogenic 
high-risk subtypes of human papillomavirus (HPV) leads to cervical cancer (zur Hausen 
2002) and over 50% of the cases are HPV-16 (Walboomers et al., 1999). In cancer 
development, HPV-16 early proteins E6 and E7 are often believed to act as oncoproteins as 
both are crucial for immortalization and transformation of cervical keratinocytes (Munger et 
al., 2004). The E6 and E7 oncogenes work synergistically to deregulate cell cycle controls 
through a variety of mechanisms. The E6 oncogene promotes ubiquitination and 
proteasomal degradation of the tumor suppressor protein p53 and also deregulates the cell 
cycle (Thomas et al., 1999). The E7 protein binds to and inactivates the function of 
retinoblastoma protein Rb and the related tumor suppressor proteins p107 and p130. It 
disrupts the complex between Rb and the E2F transcription factor family, which controls the 
expression of genes involved in cell-cycle progression. Thus, destabilization of p53 and 
hypophosphorylated pRb by the expression of two viral oncoproteins E6 and E7 promotes 
chromosomal instability, foreign DNA integration, and other mutagenic events in the cell.  
2.1 HPV Oncoproteins 
HPVs encode two major oncoproteins, E6 and E7, which are consistently expressed in 
cervical carcinomas. E6 and E7 lack intrinsic enzymatic activities and transform cells by 
stimulating cell growth and inactivating tumor suppressor pathways. Expression of HPV16 
E6/E7 oncoproteins in primary human epithelial cells causes genomic instability.  
2.1.1 E6 protein 
The E6 protein of HPV is a 18 kDa phosphoprotein, which is localized in the nucleus and in 
non-nuclear membranes.  E6 is a critical factor in tumor formation and acts to destabilize the 
tumor suppressor p53. The p53 tumor suppressor protein, in turn, regulates the 
transcription of several genes that keep cell proliferation in check by inducing cell cycle 
arrest, DNA repair, or apoptosis. The E6 protein forms a complex with p53 and the cellular 
ubiquitin ligase causing a  deregulation of the cell cycle control at the G1/S and G2/M check 
points, an important step for the replication of HPV, because a productive infection cycle is 
only possible in cells, which are in the S-phase of the cell cycle. However, this cell cycle 
manipulation can lead to activation of oncogenes or inactivation of tumor suppressors and 
consequent DNA damage cannot be repaired. This leads to genetic instability and to 
malignant transformation of high-risk HPV-infected cells (Fehrmann and Laimins 2003). 
Another important way how E6 proteins of genital HPV contribute to transformation is the 
activation of the human telomerase reverse transcriptase promoter, which controls the 
transcription of the catalytic telomerase subunit. E6 proteins of cutaneous HPV do not 
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interact with p53 or E6-AP and do not degrade p53 (Elbel et al. 1997). Furthermore E6 
proteins of both cutaneous and anogenital HPV are able to target the proapoptotic protein 
for ubiquitin-dependent degradation by assembling E6-AP, thereby inhibiting apoptosis.  
2.1.2 E7 protein 
E7 is a 11 kDa protein with a zinc finger motif. It acts as an oncogene in genital high risk 
HPV and is able to immortalize primary foreskin keratinocytes. The major part of the 
transforming potential of E7 is due to binding and induction of ubiquitin-dependent 
degradation of the tumor suppressor retinoblastoma protein (Rb) (Berezutskaya and Bagchi 
1997). The competitive binding of E7 to Rb and its degradation lead to segregation of the 
transcription factor E2F. In the G1-phase, E2F is inactivated in a complex with Rb. After 
segregation, E2F can induce the expression of genes, which are important for DNA synthesis 
and cell cycle control. Additionally E7 can bind the inhibitors of cyclin dependent kinases 
p21CIP1 and p27KIP1 and inhibit their functions (Münger et al.2001). Both events direct the 
cell into the S-phase and enable the viral replication.  
3. MicroRNA biology 
One of the most significant recent advances in biomedical research has been the discovery of ∼22-nt-long class of noncoding RNAs designated as microRNAs (miRNAs). MicroRNAs are 
small, non-coding RNAs that regulate gene expression (Ambros et al., 2003) it function by 
binding to the 3’ UTRs of their target messenger RNA (mRNA), whereby they induce 
mRNA degradation or repression of translation. The functions of miRNAs are still largely 
unknown but they appear to be integral to modulation of gene expression and cell behavior. 
These regulatory RNAs provide a unique level of posttranscriptional gene regulation that 
modulates a range of fundamental cellular processes.  
MiRNAs were first discovered in C. elegans (Lee et al., 1993). They have since been found to 
be conserved across many species, and may regulate thousands of targets via the RNAi 
pathway (Lewis et al., 2005). Most miRNAs are transcribed by RNA polymerase II, have a 
Cap, and are polyadenylated (Cai et al., 2004). They are often processed from polycistronic 
transcripts (Lee et al., 2002). Following transcription, the large primarymiRNA transcripts 
are processed into precursor-miRNAs by the protein Drosha . Pre-miRNAs are hairpin-like 
structures with characteristic 2 nt 3’ overhangs (Figure.1). They are exported to the 
cytoplasm by exportin 5 (Lund et al., 2004), where further processing into miRNA duplexes 
by the protein Dicer. MicroRNA duplexes associate with the RISC complex but only one 
strand, the mature miRNA; remains associated with it and are delivered to its target 
(Schwarz et al., 2003; Khvorova et al., 2003). The fate of target mRNAs depends on the 
degree of complementarity with the miRNA. Commonly, the 5’ 2-8 nt of the miRNA (called 
the seed sequence) is complementary to the target, and the remaining miRNA contains 
many mismatches. A low degree of complementarity results in translational repression, 
whereas a high degree of complementarity results in cleavage of the mRNA followed by its 
eventual destruction (Kim, 2005).  
To date, more than 10,000 miRNAs have been annotated in 96 species, including over 700 
human miRNAs (miRBase v14.0). More than 50% of miRNA genes are located in cancer 
associated genomic regions or in fragile sites, suggesting that miRNAs should be important 
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in cancer formation (Calin et al., 2004). Some recent studies show that miRNAs control many 
crucial biological activities, including cellular proliferation, differentiation and apoptosis 
(Esquela-Kerscher and Slack, 2006; Zhang et al., 2007). The main function of miRNA is to 
repress the expression of target mRNA by cleavage or translational silencing, which 
depends on their complementation with the 3’-untranslated region (3’UTR) of target 
mRNAs (Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006; Garzon et al., 2005). By 
using highthroughput miRNA microarray analysis, compared with the adjacent normal 
tissues, deregulation of the expression of miRNAs has been reported in different kinds of 
human cancer (Zhang et al., 2007; Lee et al., 2008), including cervical cancer (Lui et al., 2007; 
Lee et al., 2008). The aberrant expression of miRNA in cancer indicates the possible function 
of miRNAs in cancer development (Calin and Croce, 2006). Current evidence indicates that 
viruses use these miRNAs to manipulate both cellular and viral gene expression. 
Furthermore, viral infection can exert a profound impact on the cellular miRNA expression 
profile.  
 
Fig. 1. Biogenesis of MicroRNA 
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3.1 MicroRNA and cancer 
Many studies showed that miRNAs are aberrantly expressed in cancer, suggesting their role 
as a novel class of oncogenes or tumor suppressor genes. Many studies have been 
performed to investigate the contribution of miRNAs to carcinogenesis.  The findings that 
miRNAs have a role in cancer are supported by the fact that about 50% of miRNA genes are 
localized in cancer-associated genomic regions or in fragile sites or integration sites of high-
risk HPVs (Calin et al., 2004). Integration may alter miRNA expression via deletion, 
amplification, or genomic rearrangement. In a recent study, Lu et al., (2005) profiled miRNA 
expression patterns of human cancers and found differential expression for each cancer 
type. Depending on the nature of their targets, miRNAs can function as either tumor 
suppressor genes or oncogenes. For example, overexpression of miRNAs that target 
oncogenes can lead to increased destruction of these oncogenes and therefore tumor 
suppression. Conversely, overexpression of miRNAs that target tumor suppressors can 
result in increased oncogenic activity and tumor formation. Regulation mediated by these 
genes has possibly a large impact on gene expression because, according to computational 
predictions, a single miRNA can target dozens of genes. MicroRNAs have been shown to 
regulate the oncogenes Bcl 2 and Ras, as well as the tumor suppressor pRb. MiR-15 and 
miR-16 were the first miRNAs shown to be associated with cancer; they are underexpressed 
in chronic lymphocytic leukemia (CLL) (Calin et al., 2002). They regulate the Bcl-2 oncogene, 
which is overexpressed in many cancers (Cimmino   et al., 2005). The let-7 family of miRNAs 
regulates the Ras oncogenes, which contain activating mutations in about 15-30% of cancers 
(Johnson SM,  et al., 2005) and down regulation of the let-7 family of miRNAs results in the 
up regulation of Ras, which is most pronounced in lung cancers (Takamizawa J, et al., 2004). 
3.2 Altered microRNA signatures in cervical cancer 
Many authors have reported that each cancer tissue has a specific microRNA signature and 
microRNA based cancer classification is a very effective and potential tool (Lu et al., 2005).It 
is interesting to speculate that miRNA expression signatures have been shown to be 
promising biomarkers for Cervical Cancer prognosis (Xiaoxia Hu et al.,2010). Thus miRNA 
expression patterns may serve as potential biomarkers of pre-invasive cervical disease and 
potential therapeutic targets. Keeping in view the immense impact of microRNAs 
expressional profile in cancer biology, conducted surveys on expressional patterns of 
miRNAs in cervical cancer suggested that beyond HPV, microRNAs play a major role in 
cervical cancer pathogenesis and progression (Reshmi and Pillai 2008). Micro-RNA 
expression profile in cervical cancer cell lines found that of 174 miRNAs which could be 
grouped into 46 different miRNA species, miR-21, miR-24, miR-27a, and miR-205 were most 
abundant in cervical cancer or cervical intraepithelial neoplasia derived cell lines (Wang et 
al., 2008). MicroRNA array analyses for age-matched normal cervix and cervical cancer 
tissues, in combination with Northern blot verification identified deregulated miRNAs in 
cervical cancer tissues. Down regulation of with miR-126, miR-143, and miR-145, miR-218, 
and miR-424 and up regulation of miR-15b, miR-16, miR-146a, and miR- 155 had shown in 
Table 1 and 2 respectively. Functional studies showed that both miR-143 and miR-145 are 
suppressive to cell growth. When introduced into cell lines, miR-146a was found to promote 
cell proliferation. Another study suggested that overexpression of miR-17-5p, miR-20a, miR-
21, miR-92, miR-106a, and miR-155 could be considered a miRNA signature of solid tumors 
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(Volinia et al., 2006). Eighteen miRNAs were upregulated in solid tumors where 15 were 
downregulated in cervical cancer tissues. The increased expression of miR-15b, miR-16, 
miR-146a, miR-155, and miR-223 observed in cervical cancer tissues has also been implicated 
in the development of other human cancers. Another study suggests that altered miRNA 
expression patterns seen in early stage invasive squamous cell carcinomas (ISCCs) and 
normal epithelial tissues of the cervix and findings suggest that miR-127 may be a marker 
for lymph node metastasis of ISCCs and that miR-199a may be a potential therapeutic target 
for future cervical cancer therapy (Lee et al., 2008). 
 
 
miRNA Chromosome Putative Function 
hsa-miR-210 11 oncogenic 
hsa-miR-182 07 og/tsg 
hsa-miR-183 08 og/tsg 
hsa-miR-200c 12 tumour suppressor 
hsa-miR-203 14 og/tsg 
hsa-miR-193b 16 oncogenic 
hsa-miR-34a 01 og/tsg 
hsa-miR-31 11 og/tsg 
hsa-miR-210 11 og/tsg 
hsa-miR-27a 19 og/tsg 
hsa-miR-503 X og/tsg 
hsa-miR-27b 09 og/tsg 
hsa-miR-199a 19 og/tsg 
hsa-miR-199b 09 og/tsg 
hsa-miR-146a 05 og/tsg 
hsa-miR-133a 18 og/tsg 
hsa-miR-133b 06 og/tsg 
hsa-miR-214 01 og/tsg 
hsa-miR-127 14 og/tsg 
og-oncogene; tsg-tumor suppressor gene 
 
Table 1. MicroRNAs overexpressed in cervical cancer cell lines. 
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miRNA Chromosome Putative function 
hsa-miR-126 09 og/tsg 
hsa-miR-145 05 og/tsg 
hsa-miR-451 17 og/tsg 
hsa-miR-195 19 og/tsg 
hsa-miR-143 05 og/tsg 
hsa-miR-199b 09 og/tsg 
hsa-miR-1 01 og/tsg 
hsa-miR-495 14 og/tsg 
hsa-miR-497 17 og/tsg 
hsa-miR-133b 06 og/tsg 
hsa-miR-223 X og/tsg 
hsa-miR-126-AS 09 og/tsg 
hsa-miR-150 19 og/tsg 
hsa-miR-376a 14 og/tsg 
hsa-miR-214 01 og/tsg 
hsa-miR-487b 14 og/tsg 
hsa-miR-10b 02 og/tsg 
hsa-miR-218 04 og/tsg 
hsa-miR-149 02 og/tsg 
hsa-miR-203 14 og/tsg 
og-oncogene; tsg-tumor suppressor gene 
Table 2. MicroRNAs underexpressed in cervical cancer cell lines. 
3.3 Modulation of cellular microRNA regulation by HPV oncoproteins 
Deletions or mutations in miRNA genes, as well as aberrant expression of oncogenic or 
tumor-suppressive miRNAs, are common in human cancers (Calin and Croce 2006; Wang et 
al. 2008), but the causes for their aberrant expression are poorly understood. Although many 
human viruses produce their own viral miRNAs in the course of virus infection (Tang S et 
al., 2008 & Umbach et al. 2008), but recently various studies  reported on viral proteins 
regulation of cellular miRNA expression. Deregulation of oncogenic and tumor suppressive 
miRNAs in human cervical cancer is associated High-risk human papillomavirus (HPV) 
integration. Cervical cancer represents a unique tumor model for understanding how viral 
E6 and E7 oncoproteins deregulate the expression of the microRNA clusters via downstream 
targets of the transcription factors (Figure.2). It is well recognized that cellular miRNAs play 
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important roles in the regulation of cellular genes. Recent data designate that cellular 
miRNAs can also target the genetic material of invading viruses. Moreover, Latest host viral 
interaction studies of HPV integrated cervical cancer samples supports the evidence of 
interplay between the viral oncoproteins and microRNA expressions in oncogenic HPV-
infected cells. 
3.3.1 hsa-miR-34a 
Recently, miR-34a was identified as a direct transcriptional target of cellular transcription 
factor p53 (He et al. 2007; Raver-Shapira et al. 2007). This transactivation of miR-34a 
expression is triggered by the binding of p53 to a consensus p53 binding site identified in 
the miR-34a promoter region. Since HPV E6 oncoprotein destabilizes p53 during virus 
infection, one may assume a down-regulation of miR-34a expression in most cervical cancer 
tissues with oncogenic HPV infection. Interestingly, Wang et al discovery shows that at all 
stages of pathogenesis induced by the high-risk HPV types, the E6 destabilization of the 
tumor suppressor p53 down-regulates the tumor-suppressive miR-34a, leading to the 
elevated expression of cell cycle regulators and cell proliferation (Wang et al., 2009). These 
intimate interplays among viral E6, p53, miR-34a, and E7 place miR-34a in a central role in a 
well-known viral oncoprotein–tumor suppressor network. 
3.3.2 hsa-miR-23b 
Au Yeung et al., suggesting miR-23b is often downregulated in HPV-associated cervical 
cancer. Interestingly, urokinase-type plasminogen activator (uPA), the miR-23b target, is 
detected in cervical cancer, but not in normal cervical tissues. Thus, the importance of miR-
23b and uPA in HPV-associated cervical cancer development is investigated. HPV-16 E6 
oncoprotein was found to decrease the expression of miR-23b, increase the expression of 
uPA, and thus induce the migration of human cervical carcinoma SiHa and CaSki cells. uPA 
is the target gene for miR-23b as the miR repressed uPA expression and interacted with the 
3′-untranslated region of uPA mRNA. From the above, miR-23b/uPA are confirmed to be 
involved in HPV-16 E6-associated cervical cancer development ( Au Yeung et al., 2011). 
3.3.3 hsa-miR-218 
MicroRNA-218 (miR- 218) is specifically underexpressed in cell lines, cervical lesions and 
cancer tissues containing integrated HPV-16 DNA compared to the normal cervix. Martinez 
et al., studies revealed that exogenous expression of the HPV-16 E6 oncogene reduced miR-
218 expression, and conversely, RNA interference of E6/E7 oncogenes in an HPV-16 
positive cell line increased miR-218 expression. Exogenous expression of miR-218 in HPV-16 
positive cell lines decreased expression of the epithelial-specific gene LAMB3, which is 
involved in cell migration and tumorigenicity (Martinez et al., 2008) 
3.3.4 hsa-mir-29 
Yang et al established a putative HPV-associated miRNA–mRNA regulatory network, 
showing that miR-29 is the most highly enriched. Studies found that YY1 and CDK6 were 
both positively correlated with E6/E7 RNA expression and targeted by tumour-suppressive 
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miR-29 (Yang et al., 2011). Evidence of miR-29 involvement in HPV infection was further 
verified in patient samples and by various experimental approaches suggests that HPVs 
have oncogenic properties at least in part by reshaping the milieu of cellular miRNAs. miR-
29 restrains cell cycle progression and induces apoptosis via YY1 and CDK6 promoting 
malignant transformation induced by HPV, although the abnormality of miR-29 in HPV-
infected cells might be regulated in an indirect way. 
 
Fig. 2. Interaction of HPV oncoproteins and regulation of MicroRNAs in Cervical Carcinoma 
3.3.5 hsa-miR-203 
Recent studies indicated that the HPV E7 protein interferes with the normal upregulation of 
miR-203 expression upon differentiation, which may occur through the mitogen-activated 
protein (MAP) kinase/protein kinase C (PKC) pathway. Interestingly, the MAPK pathways 
induce all these transcription factors (Melar et al., 2010). Several downstream targets of p63, 
CARM-1, p21, and Bax, were also increased in E7-expressing cells, and their levels were 
inversely correlated with amounts of miR-203.Since the MAPK/protein kinase C (PKC) 
pathway is also implicated in regulating keratinocyte differentiation, studies suggests that 
miR-203 levels were affected by the MAPK/PKC pathway signaling and if HPV E7 
interfered with the activation of this pathway. 
Recent studies indicate that human cellular miRNAs can also target the genetic material of 
invading HPV viruses. It also gives the virus an opportunity to modulate the host to suite its 
needs. Thus the range of interactions possible through miRNA-mRNA cross-talk at the host-
pathogen interface is large. These interactions can be further fine-tuned in the host by 
changes in gene expression, mutations and polymorphisms. In the pathogen, the high rate of 
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mutations adds to the complexity of the interaction network. Though evidence regarding 
microRNA mediated cross-talk in viral infections is just emerging, it offers an immense 
chance not only to understand the intricacies of host-pathogen interactions but also to 
develop novel biomarkers and therapeutics. 
4. Conclusion 
On the basis of these observations, we suggest a new dimension to HPV-initiated 
carcinogenesis. HPV modulates the expression of numerous cellular microRNAs that are to 
likely contribute to viral pathogenesis. Surprisingly, recent studies have led to the 
identification of cellular microRNA regulation by HPV oncoproteins and viral regulation of 
expression of a tumor suppressor miRNAs. The known data provides evidence that this 
intimate interplay of oncoproteins and microRNAs could disclose new ways for cancer 
diagnosis, prognosis evaluator and therapy.  
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